Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIa, Xla and thrombinWONG, Pancras C; XIAOSUI JIANG.Thrombosis and haemostasis. 2010, Vol 104, Num 2, pp 302-310, issn 0340-6245, 9 p.Article

Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agentWONG, Pancras C; PINTO, Donald J. P; KNABB, Robert M et al.Cardiovascular drug reviews (Print). 2002, Vol 20, Num 2, pp 137-152, issn 0897-5957Article

Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitroXIAOSUI JIANG; CRAIN, Earl J; LUETTGEN, Joseph M et al.Thrombosis and haemostasis. 2009, Vol 101, Num 4, pp 780-782, issn 0340-6245, 3 p.Article

Apixaban Metabolism and Pharmacokinetics after Oral Administration to HumansRAGHAVAN, Nirmala; FROST, Charles E; DONGLU ZHANG et al.Drug metabolism and disposition. 2009, Vol 37, Num 1, pp 74-81, issn 0090-9556, 8 p.Article

Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor XaFEVIG, John M; CACCIOLA, Joseph; BURIAK, Joseph et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 14, pp 3755-3760, issn 0960-894X, 6 p.Article

Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moietiesCORTE, James R; TIANAN FANG; RENDINA, Alan R et al.Bioorganic & medicinal chemistry letters (Print). 2008, Vol 18, Num 9, pp 2845-2849, issn 0960-894X, 5 p.Article

Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moietiesPINTO, Donald J. P; GALEMMO, Robert A; SMALLWOOD, Angela et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 21, pp 5584-5589, issn 0960-894X, 6 p.Article

Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]- 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor XaPINTO, Donald J. P; ORWAT, Michael J; LUETTGEN, Joseph M et al.Journal of medicinal chemistry (Print). 2001, Vol 44, Num 4, pp 566-578, issn 0022-2623Article

1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaPINTO, Donald J. P; ORWAT, Michael J; ROSSI, Karen A et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 15, pp 4141-4147, issn 0960-894X, 7 p.Article

Structure-based design of novel guanidine/benzamidine mimics: Potent and orally bioavailable factor Xa inhibitors as novel anticoagulantsLAM, Patrick Y. S; CLARK, Charles G; ROSSI, Karen A et al.Journal of medicinal chemistry (Print). 2003, Vol 46, Num 21, pp 4405-4418, issn 0022-2623, 14 p.Article

Nonbenzamidine isoxazoline derivatives as factor Xa inhibitorsQUAN, Mimi L; ELLIS, Christopher D; WEXLER, Ruth R et al.Bioorganic & medicinal chemistry letters (Print). 2003, Vol 13, Num 6, pp 1023-1028, issn 0960-894X, 6 p.Article

BMS-593214, an active site-directed factor Vlla inhibitor: Enzyme kinetics, antithrombotic and antihaemostatic studiesWONG, Pancras C; LUETTGEN, Joseph M; RENDINA, Alan R et al.Thrombosis and haemostasis. 2010, Vol 104, Num 2, pp 261-269, issn 0340-6245, 9 p.Article

Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residuesQIAO, Jennifer X; XUHONG CHENG; KNABB, Robert M et al.Bioorganic & medicinal chemistry letters (Print). 2007, Vol 17, Num 5, pp 1432-1437, issn 0960-894X, 6 p.Article

Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in ratsXINKANG WANG; LIN XU; BERNARD, Roberta et al.Stroke (1970). 2003, Vol 34, Num 2, pp 468-474, issn 0039-2499, 7 p.Article

Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitorsQI HAN; DOMINGUEZ, Celia; WRIGHT, Matthew M et al.Journal of medicinal chemistry (Print). 2000, Vol 43, Num 23, pp 4398-4415, issn 0022-2623Article

Clopidogrel versus prasugrel in rabbits : Effects on thrombosis, haemostasis, platelet function and response variabilityWONG, Pancras C; CRAIN, Earl J; WATSON, Carol A et al.Thrombosis and haemostasis. 2009, Vol 101, Num 1, pp 108-115, issn 0340-6245, 8 p.Article

Highly efficacious factor Xa inhibitors containing α-substituted phenylcycloalkyl P4 moietiesQIAO, Jennifer X; KING, Sarah R; KAN HE et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 2, pp 462-468, issn 0960-894X, 7 p.Article

Discovery of 1 -(4 -methoxyphenyl ) -7 -oxo -6 -(4 -(2 -oxopiperidin -1 -yl )phenyl ) -4,5,6,7 -tetrahydro-1H -pyrazolo [3,4 -C]pyridine -3 -carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor xaPINTO, Donald J. P; ORWAT, Michael J; KAN HE et al.Journal of medicinal chemistry (Print). 2007, Vol 50, Num 22, pp 5339-5356, issn 0022-2623, 18 p.Article

Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor XaLI, Yun-Long; FEVIG, John M; WEXLER, Ruth R et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 19, pp 5176-5182, issn 0960-894X, 7 p.Article

Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro-2'-(aminosulfonyl)[1,1'-bi phenyl]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitorPRUITT, James R; PINTO, Donald J. P; HAIYING CHEN et al.Journal of medicinal chemistry (Print). 2003, Vol 46, Num 25, pp 5298-5315, issn 0022-2623, 18 p.Article

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitorHE, Kan; LUETTGEN, Joseph M; WEXLER, Ruth R et al.European journal of drug metabolism and pharmacokinetics. 2011, Vol 36, Num 3, pp 129-139, issn 0378-7966, 11 p.Article

Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitorsQUAN, Mimi L; QI HAN; FEVIG, John M et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 7, pp 1795-1798, issn 0960-894X, 4 p.Article

Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitorQUAN, Mimi L; LAM, Patrick Y. S; ALEXANDER, Richard S et al.Journal of medicinal chemistry (Print). 2005, Vol 48, Num 6, pp 1729-1744, issn 0022-2623, 16 p.Article

Nonbenzamidine tetrazole derivatives as factor Xa inhibitorsQUAN, Mimi L; ELLIS, Christopher D; WRIGHT, Matthew R et al.Bioorganic & medicinal chemistry letters (Print). 2003, Vol 13, Num 3, pp 369-373, issn 0960-894X, 5 p.Article

Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic coreFEVIG, John M; PINTO, Donald J; KNABB, Robert M et al.Bioorganic & medicinal chemistry letters (Print). 2001, Vol 11, Num 5, pp 641-645, issn 0960-894XArticle